Skip to main content

Tendai Kwaramba

Assistant Professor of Medicine
Medicine, Medical Oncology
Office hours 8AM-5PM  

Overview


Dr. Tendai Kwaramba is a physician-researcher and medical oncologist specializing in gastrointestinal malignancies and global oncology. Her research centers on improving equitable access to cancer prevention, diagnosis, treatment, and survivorship care in resource-limited settings. She leads an ASCO-Conquer Cancer Young Investigator Award–funded study evaluating the implementation of evidence-based treatment de-escalation strategies for early breast cancer in South Africa. Her work bridges health equity, implementation science, and clinical oncology, with a particular focus on optimizing care delivery and resource utilization in low- and middle-income countries.

At Duke Cancer Institute, Dr. Kwaramba is developing research infrastructure that links cancer registry and precision medicine capacity in East Africa. Her broader scholarly portfolio includes work on cancer survivorship risk modeling, early onset cancers, community engagement, disparities in palliative care delivery, and the inclusion of underrepresented populations in cancer research. Drawing on her multidisciplinary background in global health and oncology, Dr. Kwaramba aims to lead collaborative, data-driven initiatives that reduce disparities and advance equitable cancer outcomes worldwide.

Current Appointments & Affiliations


Assistant Professor of Medicine · 2025 - Present Medicine, Medical Oncology, Medicine

Recent Publications


Personalized risk assessment of frailty in long-term cancer survivors.

Journal Article J Geriatr Oncol · January 2026 INTRODUCTION: Due to the growth of the cancer survivor population, strategies to facilitate efficient delivery of survivorship care are critical to reduce the risk of adverse events associated with frailty. The objective of this study was to develop a risk ... Full text Link to item Cite

Risk of Late-Onset Depression in Long-Term Survivors of Breast, Prostate, and Colorectal Cancer.

Journal Article JAMA Netw Open · November 3, 2025 IMPORTANCE: The prevalence of depression is higher in cancer survivors than in the general population. As the long-term cancer survivor population increases, it is increasingly important to understand risk factors for late-onset depression. OBJECTIVE: To i ... Full text Link to item Cite

Risk and predictors of late second primary malignancies in long-term breast, prostate, colon, and rectal cancer survivors

Conference Journal of Clinical Oncology · January 1, 2025 Background: In older, long-term (5-year) cancer survivors, mortality risks from aging and treatment-related effects may surpass those of their index cancer. Second primary malignancies (SPMs) occurring 5-10 years post-diagnosis are understudied in older pa ... Full text Cite
View All Publications

Education, Training & Certifications


University of North Carolina, Chapel Hill · 2019 M.D.
Duke University · 2015 M.Sc.

External Links


LinkedIn Twitter